ObjectiveTo explore the curative effect and safety of TPF (docetaxel + cisplatin+5-fluorouracil) induction chemotherapy sequential combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. MethodsA total of 94 patients with locally advanced nasopharyngeal carcinoma in our hospital from November 2012 to May 2013 were selected and divided into the observation group and the control group according to the random number table, with 47 cases in each group. The observation group was treated with TPF induction chemotherapy sequential combined with concurrent chemoradiotherapy, while the control group received concurrent chemoradiotherapy. Both of the groups were treated for 2 weeks. After 3 months of treatment, the clinical curative effect of the two groups were evaluated according to the RECIST reference （in 2000）; meanwhile, the adverse reactions were graded according to the common terminology criteria of adverse events (Third Edition) (CTCAEv3.0 in 2003), and the safety of the two schemes was evaluated. ResultsThe total effective rate in the observation group (85.11%) was significantly higher than that in the control group (65.70%,P＜0.05); there was no significant difference adverse reaction between the control group(78.7%) and the observation group (80.8%, P＞0.05). ConclusionsCompare to concurrent chemoradiotherapy, TPF induction chemotherapy combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma can increase the effective rate, but will not increase the adverse reaction， which shows good security.

无